13F Pro13F Pro

ORACLE INVESTMENT MANAGEMENT INC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1012622
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare96.6%$147.5M
  • Technology2.1%$3.3M
  • Consumer Discretionary0.9%$1.3M
  • Other0.4%$564,915

AUM History

13fpro.ai/research/fund/oracle-investment-management-inc-1012622

Largest positions — Q4 2025

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/oracle-investment-management-inc-1012622

ORACLE INVESTMENT MANAGEMENT INC 13F holdings — Q4 2025

$167.9M portfolio (+4.9% QoQ) · 22 holdings · Q4 2025 13F · top 10 are 98% of the stock portfolio

Includes $15.3M of put/call options ($0 puts, $15.3M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $152.6M. Weights use the stock portfolio.

All holdings — ORACLE INVESTMENT MANAGEMENT INC (Q4 2025)

22 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
TDOC$TDOCCALLTeladoc Health, Inc.$4.5M+38%
NVAX$NVAXCALLNOVAVAX INC$4.0M-6%
ARDX$ARDXCALLARDELYX, INC.$3.5M-5%
BHVN$BHVNCALLBiohaven Ltd.$2.6M-15%
DAWN$DAWNDay One Biopharmaceuticals, Inc.$932KNew
PFE$PFECALLPFIZER INC$623KNew
— ARK ETF TRetf/fund$565KNew
SGMO$SGMOSANGAMO THERAPEUTICS, INC$435K+3%
BIIB$BIIBBIOGEN INC.$424K—
TEM$TEMTempus AI, Inc.$384KNew
TSLA$TSLATesla, Inc.$225K—
HTZ$HTZHERTZ GLOBAL HOLDINGS, INC$77KNew

What changed in Q4 2025

Against the previous quarter's 13F: 7 new, 5 added to, 5 trimmed, 5 sold out. Share-count changes; largest moves by dollar size first.

New positions (7)

  • TSHA$TSHATaysha Gene Therapies, Inc.$1.5M

    first bought this quarter

  • EWTX$EWTXEdgewise Therapeutics, Inc.$951K

    first bought this quarter

  • DAWN$DAWNDay One Biopharmaceuticals, Inc.$932K

    first bought this quarter

  • PFE$PFECALLPFIZER INC$623K

    first bought this quarter

  • ARK ETF TR$565K

    first bought this quarter

  • TEM$TEMTempus AI, Inc.$384K

    first bought this quarter

+1 more in the Excel export

Added to (5)

  • ARDX$ARDXARDELYX, INC.+25%

    now $10.9M · held 8+ qtrs, 2 adds in a row

  • TDOC$TDOCCALLTeladoc Health, Inc.+38%

    now $4.5M

  • PSNL$PSNLPersonalis, Inc.+48%

    now $2.7M · held 2 qtrs, 2 adds in a row

  • BHVN$BHVNBiohaven Ltd.+4%

    now $8.7M · held 8+ qtrs, 3 adds in a row

  • SGMO$SGMOSANGAMO THERAPEUTICS, INC+3%

    now $435K · held 2 qtrs, 2 adds in a row

Trimmed (5)

  • TDOC$TDOCTeladoc Health, Inc.-50%

    now $2.5M · held 4 qtrs

  • WGS$WGSGeneDx Holdings Corp.-0.6%

    now $115.1M · held 8+ qtrs

  • BHVN$BHVNCALLBiohaven Ltd.-15%

    now $2.6M

  • NVAX$NVAXCALLNOVAVAX INC-6%

    now $4.0M

  • ARDX$ARDXCALLARDELYX, INC.-5%

    now $3.5M

Sold out (5)

  • PLTR$PLTRPalantir Technologies Inc.was $5.4M

    held 5 qtrs

  • CNC$CNCCENTENE CORPwas $3.9M

    held 1 qtr

  • NVAX$NVAXNOVAVAX INCwas $2.1M

    held 1 qtr

  • KRANESHARES TRUSTwas $719K
  • BDSX$BDSXBIODESIX INCwas $113K

    held 1 qtr

Holdings by quarter

Every 13F ORACLE INVESTMENT MANAGEMENT INC has filed, 39 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow ORACLE INVESTMENT MANAGEMENT?

Q4 2025 13F filed with the SEC on Feb 18, 2026. Prices are closing prices as of Nov 19, 2026.

Average quality of ORACLE INVESTMENT MANAGEMENT's top 20 holdings: 35/100 (our AI quality score, weighted by position size; 14 of the 20 are scored)

Top 10 since filing

-38.7%

Value-weighted move of the 10 largest stock positions

Turnover

5%

Last quarter; 18% over the last 4

Top 10 weight

98%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

95%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

ORACLE INVESTMENT MANAGEMENT INC disclosed 22 positions worth $167.9M in its Form 13F-HR for Q4 2025 — $152.6M in common stock plus $15.3M of put/call option positions (reported at underlying notional value, not premium at risk), led by $WGS (GeneDx Holdings Corp.) at 75.4% of the equity portfolio, followed by $ARDX and $BHVN. During the quarter the fund opened 7 new positions and exited 5 — including a new stake in $TSHA and a full exit from $PLTR. The portfolio is most concentrated in Healthcare (96.6% of disclosed assets). All figures are sourced directly from ORACLE INVESTMENT MANAGEMENT INC’s Form 13F-HR filing with the SEC under CIK 1012622.

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: ORACLE INVESTMENT MANAGEMENT INC

13F Pro is an AI hedge fund tracker and stock research platform. For ORACLE INVESTMENT MANAGEMENT INC (SEC CIK: 1012622), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in ORACLE INVESTMENT MANAGEMENT INC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.